M&A / Deals Biogen to acquire RayThera for up to $1bn Pharmaceutical Business ReviewThe deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones.NeuroscienceRead full story pharminent June 19, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The deal value comprises an upfront payment and further payments tied to the achievement of future clinical and regulatory milestones. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA experts endorse Moderna’s mRNA seasonal flu shotNext: US launches probe of German ‘underpayment’ for medicines Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
